Vertex Pharmaceuticals annual ebitda margin
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals EBITDA Margin Growth & History (VRTX)
Vertex Pharmaceuticals's ebitda margin was 36.52% for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 36.52% | +36.76 pp |
| 2024 | 2024-12-31 | −0.23% | −40.90 pp |
| 2023 | 2023-12-31 | 40.66% | −9.23 pp |
| 2022 | 2022-12-31 | 49.89% | +11.50 pp |
| 2021 | 2021-12-31 | 38.39% | −9.40 pp |
| 2020 | 2020-12-31 | 47.79% | +16.46 pp |
| 2019 | 2019-12-31 | 31.33% | +8.12 pp |
| 2018 | 2018-12-31 | 23.22% | +15.80 pp |
| 2017 | 2017-12-31 | 7.42% | +3.23 pp |
| 2016 | 2016-12-31 | 4.19% | +43.38 pp |
| 2015 | 2015-12-31 | −39.19% | +69.21 pp |
| 2014 | 2014-12-31 | −108.40% | −62.06 pp |
| 2013 | 2013-12-31 | −46.34% | −51.90 pp |
| 2012 | 2012-12-31 | 5.56% | −4.99 pp |
| 2011 | 2011-12-31 | 10.55% | +474.82 pp |
| 2010 | 2010-12-31 | −464.27% | +108.81 pp |
| 2009 | 2009-12-31 | −573.08% | −327.78 pp |
| 2008 | 2008-12-31 | −245.30% | — |
Vertex Pharmaceuticals quarterly ebitda margin
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 39.10% | −1.48 pp |
| Q1 2026 | 2026-03-31 | 39.97% | +15.48 pp |
| Q4 2025 | 2025-12-31 | 39.55% | +2.72 pp |
| Q3 2025 | 2025-09-30 | 40.31% | −1.88 pp |
| Q2 2025 | 2025-06-30 | 40.57% | +171.38 pp |
| Q1 2025 | 2025-03-31 | 24.49% | −19.85 pp |
| Q4 2024 | 2024-12-31 | 36.83% | −4.78 pp |
| Q3 2024 | 2024-09-30 | 42.19% | −1.30 pp |
| Q2 2024 | 2024-06-30 | −130.81% | −173.64 pp |
| Q1 2024 | 2024-03-31 | 44.34% | +9.90 pp |
| Q4 2023 | 2023-12-31 | 41.61% | −4.94 pp |
| Q3 2023 | 2023-09-30 | 43.50% | −6.34 pp |
| Q2 2023 | 2023-06-30 | 42.83% | −9.24 pp |
| Q1 2023 | 2023-03-31 | 34.44% | −16.90 pp |
| Q4 2022 | 2022-12-31 | 46.55% | +2.57 pp |
| Q3 2022 | 2022-09-30 | 49.84% | −4.91 pp |
| Q2 2022 | 2022-06-30 | 52.07% | +52.44 pp |
| Q1 2022 | 2022-03-31 | 51.34% | −1.82 pp |
| Q4 2021 | 2021-12-31 | 43.98% | −3.64 pp |
| Q3 2021 | 2021-09-30 | 54.75% | +9.31 pp |
| Q2 2021 | 2021-06-30 | −0.37% | −49.22 pp |
| Q1 2021 | 2021-03-31 | 53.16% | +3.85 pp |
| Q4 2020 | 2020-12-31 | 47.62% | +6.75 pp |
| Q3 2020 | 2020-09-30 | 45.43% | +32.25 pp |
| Q2 2020 | 2020-06-30 | 48.85% | +17.23 pp |
| Q1 2020 | 2020-03-31 | 49.31% | +13.90 pp |
| Q4 2019 | 2019-12-31 | 40.87% | +24.03 pp |
| Q3 2019 | 2019-09-30 | 13.18% | −15.48 pp |
| Q2 2019 | 2019-06-30 | 31.62% | +6.24 pp |
| Q1 2019 | 2019-03-31 | 35.41% | +12.74 pp |
| Q4 2018 | 2018-12-31 | 16.84% | −4.97 pp |
| Q3 2018 | 2018-09-30 | 28.66% | +82.42 pp |
| Q2 2018 | 2018-06-30 | 25.39% | +12.96 pp |
| Q1 2018 | 2018-03-31 | 22.67% | −17.31 pp |
| Q4 2017 | 2017-12-31 | 21.82% | +9.81 pp |
| Q3 2017 | 2017-09-30 | −53.76% | −52.75 pp |
| Q2 2017 | 2017-06-30 | 12.42% | +8.18 pp |
| Q1 2017 | 2017-03-31 | 39.97% | +39.45 pp |
| Q4 2016 | 2016-12-31 | 12.01% | +21.09 pp |
| Q3 2016 | 2016-09-30 | −1.00% | +16.38 pp |
| Q2 2016 | 2016-06-30 | 4.24% | +98.84 pp |
| Q1 2016 | 2016-03-31 | 0.52% | +112.88 pp |
| Q4 2015 | 2015-12-31 | −9.08% | +85.89 pp |
| Q3 2015 | 2015-09-30 | −17.38% | +52.59 pp |
| Q2 2015 | 2015-06-30 | −94.59% | +25.60 pp |
| Q1 2015 | 2015-03-31 | −112.36% | +56.71 pp |
| Q4 2014 | 2014-12-31 | −94.97% | −97.07 pp |
| Q3 2014 | 2014-09-30 | −69.97% | −18.52 pp |
| Q2 2014 | 2014-06-30 | −120.19% | −108.45 pp |
| Q1 2014 | 2014-03-31 | −169.06% | −41.63 pp |
| Q4 2013 | 2013-12-31 | 2.09% | +8.29 pp |
| Q3 2013 | 2013-09-30 | −51.45% | −53.69 pp |
| Q2 2013 | 2013-06-30 | −11.74% | −11.24 pp |
| Q1 2013 | 2013-03-31 | −127.43% | −150.27 pp |
| Q4 2012 | 2012-12-31 | −6.20% | −47.67 pp |
| Q3 2012 | 2012-09-30 | 2.24% | −31.66 pp |
| Q2 2012 | 2012-06-30 | −0.50% | +136.86 pp |
| Q1 2012 | 2012-03-31 | 22.84% | +227.89 pp |
| Q4 2011 | 2011-12-31 | 41.47% | +283.26 pp |
| Q3 2011 | 2011-09-30 | 33.90% | +844.28 pp |
| Q2 2011 | 2011-06-30 | −137.37% | +373.86 pp |
| Q1 2011 | 2011-03-31 | −205.05% | +475.76 pp |
| Q4 2010 | 2010-12-31 | −241.79% | +166.42 pp |
| Q3 2010 | 2010-09-30 | −810.38% | −243.73 pp |
| Q2 2010 | 2010-06-30 | −511.23% | +272.56 pp |
| Q1 2010 | 2010-03-31 | −680.81% | −35.54 pp |
| Q4 2009 | 2009-12-31 | −408.20% | — |
| Q3 2009 | 2009-09-30 | −566.65% | — |
| Q2 2009 | 2009-06-30 | −783.79% | — |
| Q1 2009 | 2009-03-31 | −645.27% | — |
Vertex Pharmaceuticals ebitda margin trends
Over the last five fiscal years, Vertex Pharmaceuticals's ebitda margin decreased from 47.79% to 36.52%, a change of −11.27 percentage points. The latest reported quarter, Q2 2026, shows 39.10%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗Community posts
Vertex adds detailed kidney-response data and launches patient-experience trial
Vertex ($VRTX) released additional Phase 3 RAINIER findings for povetacicept in IgA nephropathy. At week 36, 42.2% of treated participants achieved a urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% receiving p ...
